



To: Jai Medical Systems Providers
From: BioScrip
Date: December 31, 2013
Subject: 4th Quarter P&T Changes and Important Announcements

Effective immediately, the following products will be added to the Jai formulary:

- Benzonatate
- Guaifenesin AC
- Chlorhexidine Gluconate Oral Rinse
- Hydrocodone 5/325 (QL = 180 tablets/month)
- Nicotine gum (QL = 336 pieces/month and max total of 6 months of therapy every 365 days)
- Nicotine lozenges (QL = 360 pieces/month and max total of 6 months of therapy every 365 days)
- Nicotine patches (QL = 30 patches/month and max total of 6 months of therapy every 365 days)

The following drug is now available without prior authorization:

- Lidoderm (QL = 90 patches/month)

Effective immediately, the following products will be available with an approved prior authorization:

- Nicotine inhaler (QL = 336 cartridges/6 months)
 - Documented failure of gum, lozenge, patches, or Chantix for 30 days within the last 120 days.
- Nicotine nasal spray (QL = 18 bottles/6months)
 - Documented failure of gum, lozenge, patches, or Chantix for 30 days within the last 120 days.
- Tudorza Pressair (QL = 1 inhaler/month)
 - Indication = long-term maintenance treatment of bronchospasm associated with COPD (including bronchitis and emphysema)
 - Criteria =
 - Diagnosis of COPD and
 - Must be greater than 18 years of age and
 - Documented inadequate response or intolerance to Spiriva

Providers can contact BioScrip's Prior-Authorization Department at 800-555-8513 for assistance with PA requests or questions regarding clinical guidelines. Our PA Department is available Monday through Friday from 8:30 am-5:30 pm EST. For assistance with PA requests during non-business hours please contact our 24 hour customer service department at 800-213-5640.